Stock Analiz

Jupiter Neurosciences, Inc. JUNS

Biotechnology: Pharmaceutical Preparations · IPO 2024 · data as of November 13, 2026

$1.76Market cap $2M
Open the interactive analysis →

Jupiter Neurosciences, Inc. (JUNS) is a healthcare company listed in the US with a market value of about $2M. In fiscal year 2025 it had revenue of $21796 and net income of -$9M, a net margin of -39662.8%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -130%.

About Jupiter Neurosciences

Jupiter Neurosciences is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2024. It was profitable in 0 of the last 3 years in our data. It spends 9573% of revenue on research and development.

Score: 0.4 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S106.5
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-312.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-39662.8%
ROIC (5-yr avg.)-129.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 3 years

Fiscal year202520242023
Revenue$21796$0—
Net income-$9M-$2M-$5M
Free cash flow-$5M—-$480953
EPS (diluted)$-0.25$-0.08$-0.18
Net margin-39662.8%——
ROIC-201.8%-57.6%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Jupiter Neurosciences pay a dividend?

Not currently.

Is Jupiter Neurosciences a good stock to buy?

We do not give buy or sell advice. Jupiter Neurosciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.